KM Research Hub
← 返回论文库
无 KM 图 入排:待复核 图源:可得 入排置信度 0.45

Main results of a randomized controlled trial (RNPLS-01): efficacy and safety of ramucirumab combined with nab-paclitaxel, lobaplatin, and S-1 in neoadjuvant therapy for advanced gastric cancer.

Juan Wang, Fan Feng, Kunli Du, Xisheng Yang, Shushang Liu, Chunsheng Xu, Mengbin Li, Zhaobang Tan, Xiaohua Li, Shiqi Wang, Xuewen Yang, Shisen Li, Pengfei Yu, Jiangpeng Wei, Guanghui Xu, Liu Hong, Jianyong Zheng, Jianjun Yang

Int J Surg 111(11) 8060-8069

PMID40693968
PMCIDPMC12626509
DOI10.1097/JS9.0000000000002893
发表日期2025-07-22
入排依据:The trial is a Phase III randomized controlled trial in oncology with a drug intervention and reports primary results. However, it lacks any explicit time-to-event efficacy endpoint (e.g., OS, PFS, DFS) or associated Kaplan-Meier/HR analysis, which is a required criterion for eligibility.
已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:瀑布图;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other。
摘要

摘要

OBJECTIVE/BACKGROUND: The RNPLS-01 trial aimed to evaluate the efficacy and safety of ramucirumab (a VEGFR2 antagonist) combined with nab-paclitaxel, lobaplatin, and S-1 (RNPLS group) versus nab-paclitaxel, lobaplatin, and S-1 alone (NPLS group) in neoadjuvant therapy for advanced gastric cancer (GC), as part of the RNPLS-01 prospective randomized controlled trial. METHODS AND ANALYSIS: RNPLS-01 trial enrolled 140 patients with advanced GC across two cohorts (neoadjuvant therapy: n = 70; conversion therapy: n = 70). This report focuses on the neoadjuvant cohort where patients were randomized 1:1 to receive either RNPLS (n = 35) or NPLS (n = 35). Primary endpoint was pathological complete response (pCR). Secondary endpoints included R0 resection rate, objective response rate (ORR), disease control rate (DCR), and adverse events (AEs). RESULTS: The RNPLS group demonstrated significant improvements in post-operative T stage ( P = 0.008), N stage ( P = 0.001), and AJCC (American Joint Committee on Cancer) clinical stage ( P = 0.003) compared to controls. The RNPLS group demonstrated significantly higher pCR rates compared to the NPLS group (22.9% vs. 2.9%, P <0.0001). The R0 resection rate was 85.7% in the RNPLS group versus 82.9% in the NPLS group. The RNPLS group achieved a significantly higher ORR compared to the NPLS group (68.6% vs. 25.7%, P = 0.001), while DCRs were comparable between the two groups (94.3% vs. 77.1%, P = 0.055). Treatment-related adverse events (TRAEs) were confined to Grade 1-2 severity, with no Grade 3-4 events reported in either group. The RNPLS group showed a TRAE incidence of 80.0%, versus 88.6% in the NPLS group ( P = 0.324). Neither group exhibited surgical complications during the study period. CONCLUSION: Ramucirumab combined with nab-paclitaxel, lobaplatin, and S-1 significantly enhances the pCR rate and ORR in neoadjuvant therapy of locally advanced GC patients, while maintaining an acceptable safety profile.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. CONSORT diagram for the RNPLS-01 trial key inclusion criteria, enrolment, allocation, neoadjuvant therapy, radical surgery, study endpoints, and follow-up.
非 KM Figure
Figure 2Figure 2. The efficacy of neoadjuvant therapy in two arms of RNPLS-01 trial. (A-C). Sankey chart showing the relationship between pre-neoadjuvant therapy and post-neoadjuvant therapy T stage, N stage and AJCC clinical stage. (A) T stage; (B) N stage; (C) AJCC clinical stage. (D). Best response based on tumor burden. Waterfall plot of best response for best percentage change in target lesions from baseline two arms. PR, partial response; SD, stable disease; PD, progressive disease. (E). TRG based on tumor burden. Waterfall plot for TRG based on best percentage change in target lesions from baseline two arms.
非 KM Figure
Figure 3Figure 3. Treatment-related adverse events in the two arms of the RNPLS-01 trial.
非 KM Figure
Figure 4Figure 4. VEGFR2, CD31, and HIF1α expression in patients with TRG Grade 1 and TRG Grade 3 from both RNPLS and NPLS group.
非 KM Figure